Scientist, Oncology Bioinformatics

Responsibilities

• Analyze and integrate multi-omics datasets (e.g., WES/WGS, RNA-seq, single-cell) to characterize tumor antigen landscapes
• Apply computational methods to support antigen discovery efforts and investigate tumor-immune interactions
• Leverage internal and public datasets (e.g., TCGA, GTEx, IEDB) for biomarker exploration and hypothesis generation
• Develop and maintain reproducible analysis workflows using Python, R, and cloud-based infrastructure (AWS)
• Collaborate with cross-functional teams in immunology, oncology, and translational research to support experimental design
• Communicate results clearly through presentations and documentation to support team decision-making

Requirements

• Ph.D. or M.S. with 4+ years of experience in Bioinformatics, Computational Biology, or a related field
• Experience with high-throughput sequencing data analysis, including DNA-seq and RNA-seq
• Proficiency in Python and/or R for data analysis
• Experience working in cloud environments (e.g., AWS)
• Demonstrated ability to apply computational approaches to biological or early-stage translational research problems
• Ability to work onsite full-time at Moderna's Cambridge, MA location

Preferred Qualifications

• Exposure to immuno-oncology, cancer vaccines, tumor immunology, or computational immunology
• Familiarity with neoantigen prediction approaches, including HLA typing and peptide-MHC binding tools (e.g., NetMHCpan)
• Experience with immunogenomics resources such as IEDB and TCGA
• Strong collaboration and communication skills in a team-oriented environment

Benefits

• Best-in-class healthcare coverage and voluntary benefit programs
• Holistic well-being support including fitness, mindfulness, and mental health resources
• Family planning benefits including fertility, adoption, and surrogacy support
• Generous paid time off, including vacation, sabbatical, and global recharge days
• Savings and investment opportunities

About the Company

Moderna is pioneering the development of a new class of drugs made of messenger RNA (mRNA). We are building the leading mRNA technology platform and the infrastructure to reimagine how medicines are created and delivered to patients worldwide.